<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085834</url>
  </required_header>
  <id_info>
    <org_study_id>Zinc study</org_study_id>
    <nct_id>NCT05085834</nct_id>
  </id_info>
  <brief_title>Zinc Effect on Inflammation and Cardiovascular Risk in HIV</brief_title>
  <official_title>Zinc Effect on Inflammation and Cardiovascular Risk in HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of short-term zinc supplementation on improving inflammation, metabolic,&#xD;
      and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will focus on subjects with documented zinc deficiency (levels &lt;75 µg/dl) as group&#xD;
      most likely to benefit from the zinc supplementation. We also acknowledge that zinc may be&#xD;
      beneficial in all HIV subjects, regardless of the plasma zinc level; however initial studies&#xD;
      should be done in subjects with low zinc levels as they are more likely to benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double-blind randomized placebo-controlled trial 2:1 Patients will be given zinc gluconate capsules at a dose of 90 mg elemental zinc daily or matching placebo for 24 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, study staff, and the study statistician will be blinded to treatment allocation (zinc gluconate or placebo capsules). The research staff as well as the principle investigator will remain blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of zinc supplementation in HIV-infected subjects</measure>
    <time_frame>24 weeks</time_frame>
    <description>To examine whether zinc is safe and effective at increasing zinc levels in HIV-infected subjects with zinc deficiency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of zinc supplementation in HIV-infected subjects</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Changes in markers of inflammation and immune activation:</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Inflammation</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Zinc Deficiency</condition>
  <arm_group>
    <arm_group_label>zinc gluconate tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zinc gluconate pills at a dose of 90 mg daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc Gluconate</intervention_name>
    <description>Zinc supplementation</description>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_label>zinc gluconate tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Documentation of an HIV-1 RNA level of ≤400 copies/mL in the last 4 months prior to&#xD;
             study entry&#xD;
&#xD;
          -  Male or Female age ≥18 years&#xD;
&#xD;
          -  Zinc level ≤0.75 mg/L in the last 60 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Known cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Grace A McComsey, MD, FIDSA</last_name>
    <phone>216-844-2739</phone>
    <email>Grace.McComsey@UHhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle Labbato, BSN</last_name>
    <phone>216-844-2739</phone>
    <email>Danielle.Labbato@UHhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Grace McComsey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Zinc</keyword>
  <keyword>inflammation</keyword>
  <keyword>CVD risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

